An observational study in Glioma (Diagnosis), sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Beijing Tiantan Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Glioma by Beijing Tiantan Hospital — 10 open to participants now, 11 under way, none of them phase 3. Glioma · Beijing Tiantan Hospital.
Among the 14 studies in Glioma by Beijing Tiantan Hospital, this one is the only one that started in 2026, is one of 4 observational ones, reaches primary completion later than 7 of the 10 other live ones, and was the 14th registered.
1,453 studies on the registry are indexed under Glioma; 349 are open to participants now.
Browse Glioma studies →10 of the 14 studies in Glioma by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–80
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 0–18
Beijing Tiantan Hospital · Sites in China
By country, each count listing its studies:
Of the 267 Glioma studies recruiting now, 164 (61%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 90 across 273 observational studies indexed under Glioma.
Median enrollment 98 across the 10 interventional studies, 375 across the 4 observational. Of the 1 that completed or were terminated, 1 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Tiantan Hospital is the lead sponsor of 493 studies on the registry; 297 are open to participants now.
2 of the studies in Glioma by Beijing Tiantan Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07940231Beijing Tiantan HospitalProspective Study of Intraoperative Brain Tumor Photographs for Pathological and Molecular Classification | 2026-11-30 |
| NCT06396481Beijing Tiantan HospitalClinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma | 2026-12-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Glioma by Beijing Tiantan Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational cohort study will evaluate the diagnostic performance and workflow feasibility of a prespecified locked artificial intelligence model that analyzes smartphone-based natural-light gross images of fresh surgical tissue together with participant age. Approximately 400 consecutive adults undergoing initial surgery for suspected intracranial adult-type diffuse glioma will be enrolled at Beijing Tiantan Hospital, Capital Medical University, between July and September 2026. Images will be acquired before frozen-section processing according to a standardized operating procedure. Model outputs will be generated in silent mode and will not be shown to the surgical or pathology teams and will not alter diagnosis or treatment. The locked model score will be compared with the final IDH mutation reference standard derived from permanent histopathology, immunohistochemistry, and indicated molecular testing. The primary objective is to estimate patient-level discrimination for IDH-mutant versus IDH-wildtype tumors. Secondary objectives include fixed-threshold performance, precision-recall performance, calibration, end-to-end technical success, and prespecified model abstention, if an abstention rule is locked before enrollment.
Eligible participants will be enrolled consecutively, and a screening log will document all exclusions. Fresh ex vivo tumor tissue will be photographed before freezing. Images will be deidentified and linked through a participant-surgery-specimen-image hierarchy. The locked SNAP-IDH model will segment the tumor region of interest, permit blinded quality confirmation or editing, and combine frozen iBOT image features with age using a radial basis function support vector machine. The output is a research model score rather than a clinically calibrated absolute risk. A score of frozen yoden or will be classified as IDH-mutant. Model outputs will remain hidden from all clinical decision makers. No retraining, hyperparameter tuning, threshold selection, or recalibration will use the prospective cohort. Diagnostic accuracy will be analyzed at the participant level. Image-acquisition, segmentation, inference, and reference-standard failures will be retained in the study flow and reported separately from complete-case diagnostic performance.
Consecutive adults undergoing initial surgery for suspected intracranial adult diffuse glioma at the participating facility
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: Smartphone Nature-image AI prediction of IDH status (SNAP-IDH)
Consecutive adults undergoing initial surgery for suspected intracranial adult-type diffuse glioma will undergo standardized research imaging of fresh surgical tissue. Locked model outputs will not influence routine surgery, frozen-section assessment, permanent pathology, molecular testing, or treatment.
Patient-Level Area Under the Precision-Recall Curve of the Locked SNAP-IDH Score for IDH Mutation Status
Area under the precision-recall curve (AUPRC) calculated using one locked SNAP-IDH score per patient and the final reference-standard isocitrate dehydrogenase (IDH) mutation status, with IDH-mutant status as the positive class. AUPRC ranges from 0 to 1, with higher values indicating better performance.
Time frame: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
Patient-Level Sensitivity of SNAP-IDH for IDH Mutation Status at the Prespecified Threshold
Percentage of patients with reference-standard isocitrate dehydrogenase (IDH)-mutant status classified as IDH-mutant by SNAP-IDH at the prespecified, locked classification threshold. Sensitivity is calculated as true positives divided by the sum of true positives and false negatives, multiplied by 100.
Time frame: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
Patient-Level Specificity of SNAP-IDH for IDH Mutation Status at the Prespecified Threshold
Percentage of patients with reference-standard isocitrate dehydrogenase (IDH)-wildtype status classified as IDH-wildtype by SNAP-IDH at the prespecified, locked classification threshold. Specificity is calculated as true negatives divided by the sum of true negatives and false positives, multiplied by 100.
Time frame: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
Patient-Level Brier Score of the Locked SNAP-IDH Predicted Probability for IDH Mutation Status
Mean squared difference between each patient's locked SNAP-IDH predicted probability of isocitrate dehydrogenase (IDH) mutation and the final reference-standard status, coded as 1 for IDH-mutant and 0 for IDH-wildtype. The Brier score ranges from 0 to 1, with lower values indicating lower prediction error.
Time frame: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Nov 2026, 4 months after the start.
Of 113 non-industry observational studies under Glioma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 104. This study's planned 4 months is below that.
Counting every sponsor, half of 123 studies reached it within 60 months; a quarter within 29 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.